Dr. David D. Pham, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Texas A & M University System, Hsc, College of Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 181
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Texas A & M University System, Hsc, College of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
WI license 69643-20 -
Advanced Heart Failure and Transplant Cardiology Physician
WI license 69643-20
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Wi Hospitals & Clinics Authority Madison, WI
- Unitypoint Health - Meriter Madison, WI
- Thedacare Regional Med Ctr - Neenah Neenah, WI
- Uw Health Rockford, IL
- St Vincent Hospital Green Bay, WI
Medical groups
- University of Wisconsin Medical Foundation Inc (2,553 clinicians)
- Swedishamerican Hospital (389 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 181
- Services billed
- 491
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 93 | 83 |
| Insertion of needle into vein for collection of blood sample | 84 | 21 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 70 | 31 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 39 | 11 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 30-39 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Entresto (sacubitril/valsartan) Other prescribers in Madison, WI | 220 |
| Vyndamax (tafamidis) | 188 |
| Furosemide Other prescribers in Madison, WI | 118 |
| Carvedilol Other prescribers in Madison, WI | 117 |
| Metoprolol Succinate Other prescribers in Madison, WI | 114 |
| Spironolactone Other prescribers in Madison, WI | 110 |
| Potassium Chloride Other prescribers in Madison, WI | 103 |
| Atorvastatin Calcium Other prescribers in Madison, WI | 71 |
| Pravastatin Sodium Other prescribers in Madison, WI | 65 |
| Amlodipine Besylate Other prescribers in Madison, WI | 65 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $90,129 in research payments for these studies, mostly to the institutions running them.
- A phase 3,radomized,double-blind,placebo-controlled,multicenter study to evaluate the efficacy and safety of amyloid depleter ALXN2220 in adult participants wiith transthyretin amyloid cardiomyopathy ATTR CM
Alexion Pharmaceuticals, Inc. - An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Ionis Pharmaceuticals, Inc. · Enrolling by invitation · NCT05667493 - CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Ionis Pharmaceuticals, Inc. · Completed · NCT04136171
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.